The flavanol (-)-epigallocatechin 3-gallate inhibits amyloid formation by islet amyloid polypeptide, disaggregates amyloid fibrils, and protects cultured cells against IAPP-induced toxicity.

Islet amyloid polypeptide (IAPP, amylin) is the major protein component of the islet amyloid deposits associated with type 2 diabetes. The polypeptide lacks a well-defined structure in its monomeric state but readily assembles to form amyloid. Amyloid fibrils formed from IAPP, intermediates generated in the assembly of IAPP amyloid, or both are toxic to β-cells, suggesting that islet amyloid formation may contribute to the pathology of type 2 diabetes. There are relatively few reported inhibitors of amyloid formation by IAPP. Here we show that the tea-derived flavanol, (-)-epigallocatechin 3-gallate [(2R,3R)-5,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)-3,4-dihydro-2H-1-benzopyran-3-yl 3,4,5-trihydroxybenzoate] (EGCG), is an effective inhibitor of in vitro IAPP amyloid formation and disaggregates preformed amyloid fibrils derived from IAPP. The compound is thus one of a very small set of molecules which have been shown to disaggregate IAPP amyloid fibrils. Fluorescence-detected thioflavin-T binding assays and transmission electron microscopy confirm that the compound inhibits unseeded amyloid fibril formation as well as disaggregates IAPP amyloid. Seeding studies show that the complex formed by IAPP and EGCG does not seed amyloid formation by IAPP. In this regard, the behavior of IAPP is similar to the reported interactions of Aβ and α-synuclein with EGCG. Alamar blue assays and light microscopy indicate that the compound protects cultured rat INS-1 cells against IAPP-induced toxicity. Thus, EGCG offers an interesting lead structure for further development of inhibitors of IAPP amyloid formation and compounds that disaggregate IAPP amyloid.

[1]  R. Hamid,et al.  Comparison of alamar blue and MTT assays for high through-put screening. , 2004, Toxicology in vitro : an international journal published in association with BIBRA.

[2]  J. Carver,et al.  (-)-epigallocatechin-3-gallate (EGCG) maintains kappa-casein in its pre-fibrillar state without redirecting its aggregation pathway. , 2009, Journal of molecular biology.

[3]  P. Westermark,et al.  Formation of amyloid in human pancreatic islets transplanted to the liver and spleen of nude mice , 2003, Upsala journal of medical sciences.

[4]  M. Engelhard,et al.  Green tea extracts interfere with the stress‐protective activity of PrPC and the formation of PrPSc , 2008, Journal of neurochemistry.

[5]  M. Goedert,et al.  Inhibition of α‐synuclein fibril assembly by small molecules: Analysis using epitope‐specific antibodies , 2009, FEBS letters.

[6]  S. Gauthier,et al.  Alzhemed: a potential treatment for Alzheimer's disease. , 2007, Current Alzheimer research.

[7]  D. Raleigh,et al.  The role of His-18 in amyloid formation by human islet amyloid polypeptide. , 2005, Biochemistry.

[8]  R. Holman,et al.  Islet amyloid, increased A-cells, reduced B-cells and exocrine fibrosis: quantitative changes in the pancreas in type 2 diabetes. , 1988, Diabetes research.

[9]  Adam Douglass,et al.  Mechanism of Prion Propagation: Amyloid Growth Occurs by Monomer Addition , 2004, PLoS biology.

[10]  G. Cooper.  Amylin compared with calcitonin gene-related peptide: structure, biology, and relevance to metabolic disease. , 1994, Endocrine reviews.

[11]  P. Fraser,et al.  Inhibitors of islet amyloid polypeptide fibrillogenesis, and the treatment of type-2 diabetes , 2003, Letters in Peptide Science.

[12]  H. Mihara,et al.  Peptide and protein mimetics inhibiting amyloid beta-peptide aggregation. , 2008, Accounts of chemical research.

[13]  Tuomas P. J. Knowles,et al.  An Analytical Solution to the Kinetics of Breakable Filament Assembly , 2009, Science.

[14]  D. Ehrnhoefer,et al.  EGCG remodels mature α-synuclein and amyloid-β fibrils and reduces cellular toxicity , 2010, Proceedings of the National Academy of Sciences.

[15]  Christopher G. Adda,et al.  Inhibition by flavonoids of amyloid-like fibril formation by Plasmodium falciparum merozoite surface protein 2. , 2010, Biochemistry.

[16]  Ehud Gazit,et al.  Inhibition of islet amyloid polypeptide fibril formation: a potential role for heteroaromatic interactions. , 2004, Biochemistry.

[17]  D. Raleigh,et al.  Two-dimensional infrared spectroscopy provides evidence of an intermediate in the membrane-catalyzed assembly of diabetic amyloid. , 2009, The journal of physical chemistry. B.

[18]  H. Levine.  Thioflavine T interaction with amyloid β-sheet structures , 1995 .

[19]  Fanling Meng,et al.  A single-point mutation converts the highly amyloidogenic human islet amyloid polypeptide into a potent fibrillization inhibitor. , 2007, Journal of the American Chemical Society.

[20]  D. Raleigh,et al.  Recovery and purification of highly aggregation-prone disulfide-containing peptides: application to islet amyloid polypeptide. , 2006, Analytical biochemistry.

[21]  J. Tan,et al.  Oral administration of green tea epigallocatechin-3-gallate (EGCG) reduces amyloid beta deposition in transgenic mouse model of Alzheimer's disease , 2006, Experimental Neurology.

[22]  Martin L. Duennwald,et al.  A synergistic small molecule combination directly eradicates diverse prion strain structures , 2009, Nature chemical biology.

[23]  D. Selkoe,et al.  Cell biology of protein misfolding: The examples of Alzheimer's and Parkinson's diseases , 2004, Nature Cell Biology.

[24]  Robert A. Rizza,et al.  β-Cell Deficit and Increased β-Cell Apoptosis in Humans With Type 2 Diabetes , 2003, Diabetes.

[25]  Robert A Rizza,et al.  Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. , 2003, Diabetes.

[26]  B. Frei,et al.  Tea Catechins and Polyphenols: Health Effects, Metabolism, and Antioxidant Functions , 2003, Critical reviews in food science and nutrition.

[27]  R. Neubig,et al.  Small Molecule Protein–Protein Interaction Inhibitors as CNS Therapeutic Agents: Current Progress and Future Hurdles , 2009, Neuropsychopharmacology.

[28]  H. Hou,et al.  Green tea epigallocatechin-3-gallate (EGCG) reduces β-amyloid mediated cognitive impairment and modulates tau pathology in Alzheimer transgenic mice , 2008, Brain Research.

[29]  P E Fraser,et al.  Identification of a novel human islet amyloid polypeptide beta-sheet domain and factors influencing fibrillogenesis. , 2001, Journal of molecular biology.

[30]  W. Saeger,et al.  Immunohistology of islet amyloid polypeptide in diabetes mellitus: Semi-qantitative studies in a post-mortem series , 2005, Virchows Archiv A.

[31]  A. Kapurniotu,et al.  Design of a mimic of nonamyloidogenic and bioactive human islet amyloid polypeptide (IAPP) as nanomolar affinity inhibitor of IAPP cytotoxic fibrillogenesis , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[32]  S. Kahn,et al.  Islet amyloid: a long-recognized but underappreciated pathological feature of type 2 diabetes. , 1999, Diabetes.

[33]  H. Waldmann,et al.  Small-molecule inhibitors of islet amyloid polypeptide fibril formation. , 2008, Angewandte Chemie.

[34]  Olle Korsgren,et al.  Widespread amyloid deposition in transplanted human pancreatic islets. , 2008, The New England journal of medicine.

[35]  D. Steiner,et al.  Islet amyloid polypeptide. A new beta cell secretory product related to islet amyloid deposits. , 1990, The Journal of biological chemistry.

[36]  C. Wernstedt,et al.  A novel peptide in the calcitonin gene related peptide family as an amyloid fibril protein in the endocrine pancreas. , 1986, Biochemical and biophysical research communications.

[37]  A. Miranker,et al.  The mechanism of insulin action on islet amyloid polypeptide fiber formation. , 2004, Journal of molecular biology.

[38]  David Morgan,et al.  Green Tea Epigallocatechin-3-Gallate (EGCG) Modulates Amyloid Precursor Protein Cleavage and Reduces Cerebral Amyloidosis in Alzheimer Transgenic Mice , 2005, The Journal of Neuroscience.

[39]  D. Raleigh,et al.  Islet amyloid deposition limits the viability of human islet grafts but not porcine islet grafts , 2010, Proceedings of the National Academy of Sciences.

[40]  D. W. Hayden,et al.  Amyloid fibrils in human insulinoma and islets of Langerhans of the diabetic cat are derived from a neuropeptide-like protein also present in normal islet cells. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[41]  D. Raleigh,et al.  Analysis of amylin cleavage products provides new insights into the amyloidogenic region of human amylin. , 1999, Journal of molecular biology.

[42]  Jen-kun Lin,et al.  Epigallocatechin gallate (EGCG) suppresses beta-amyloid-induced neurotoxicity through inhibiting c-Abl/FE65 nuclear translocation and GSK3 beta activation. , 2009, Neurobiology of aging.

[43]  D. Raleigh,et al.  A critical assessment of the role of helical intermediates in amyloid formation by natively unfolded proteins and polypeptides. , 2009, Protein engineering, design & selection : PEDS.

[44]  D. Raleigh,et al.  Rifampicin does not prevent amyloid fibril formation by human islet amyloid polypeptide but does inhibit fibril thioflavin-T interactions: implications for mechanistic studies of beta-cell death. , 2008, Biochemistry.

[45]  Bruce A. Yankner,et al.  Pancreatic islet cell toxicity of amylin associated with type-2 diabetes mellitus , 1994, Nature.

[46]  S. Radford,et al.  Systematic analysis of nucleation-dependent polymerization reveals new insights into the mechanism of amyloid self-assembly , 2008, Proceedings of the National Academy of Sciences.

[47]  D. Ehrnhoefer,et al.  EGCG redirects amyloidogenic polypeptides into unstructured, off-pathway oligomers , 2008, Nature Structural &Molecular Biology.

[48]  Per Westermark,et al.  Islet amyloid: a critical entity in the pathogenesis of type 2 diabetes. , 2004, The Journal of clinical endocrinology and metabolism.

[49]  D. Raleigh,et al.  Incorporation of pseudoproline derivatives allows the facile synthesis of human IAPP, a highly amyloidogenic and aggregation-prone polypeptide. , 2005, Organic letters.

[50]  P. Fraser,et al.  Arresting amyloidosis in vivo using small-molecule anionic sulphonates or sulphates: implications for Alzheimer's disease , 1995, Nature Medicine.

[51]  Roland Winter,et al.  Inhibiting Islet Amyloid Polypeptide Fibril Formation by the Red Wine Compound Resveratrol , 2009, Chembiochem : a European journal of chemical biology.

[52]  C. Verchere,et al.  Islet amyloid polypeptide and type 2 diabetes , 2003, Experimental Gerontology.

[53]  J. Sowers,et al.  Longitudinal ultrastructure study of islet amyloid in the HIP rat model of type 2 diabetes mellitus. , 2007, Experimental biology and medicine.

[54]  R. L. Hull,et al.  Amyloid formation results in recurrence of hyperglycaemia following transplantation of human IAPP transgenic mouse islets , 2008, Diabetologia.

[55]  Jonathan Weissman,et al.  Small-molecule aggregates inhibit amyloid polymerization. , 2008, Nature chemical biology.

[56]  Ehud Gazit,et al.  Inhibition of Amyloid Fibril Formation by Polyphenols: Structural Similarity and Aromatic Interactions as a Common Inhibition Mechanism , 2006, Chemical biology & drug design.

[57]  R. Turner,et al.  Purification and characterization of a peptide from amyloid-rich pancreases of type 2 diabetic patients. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[58]  J. Hutton.  The insulin secretory granule , 1989, Diabetologia.

[59]  R. Turner,et al.  ISLET AMYLOID FORMED FROM DIABETES-ASSOCIATED PEPTIDE MAY BE PATHOGENIC IN TYPE-2 DIABETES , 1987, The Lancet.

[60]  Jen-kun Lin,et al.  Epigallocatechin gallate (EGCG) suppresses β-amyloid-induced neurotoxicity through inhibiting c-Abl/FE65 nuclear translocation and GSK3β activation , 2009, Neurobiology of Aging.

[61]  J. Kistler,et al.  The aggregation potential of human amylin determines its cytotoxicity towards islet β‐cells , 2006, The FEBS journal.